PcrG protects the two long helical oligomerization domains of PcrV, by an interaction mediated by the intramolecular coiled-coil region of PcrG by Basu, Abhishek et al.
Basu et al. BMC Structural Biology 2014, 14:5
http://www.biomedcentral.com/1472-6807/14/5RESEARCH ARTICLE Open AccessPcrG protects the two long helical oligomerization
domains of PcrV, by an interaction mediated by
the intramolecular coiled-coil region of PcrG
Abhishek Basu, Urmisha Das, Supratim Dey and Saumen Datta*Abstract
Background: PcrV is a hydrophilic translocator of type three secretion system (TTSS) and a structural component of
the functional translocon. C-terminal helix of PcrV is essential for its oligomerization at the needle tip. Conformational
changes within PcrV regulate the effector translocation. PcrG is a cytoplasmic regulator of TTSS and forms a high affinity
complex with PcrV. C-terminal residues of PcrG control the effector secretion.
Result: Both PcrV and PcrG-PcrV complex exhibit elongated conformation like their close homologs LcrV and LcrG-LcrV
complex. The homology model of PcrV depicts a dumbbell shaped structure with N and C-terminal globular
domains. The grip of the dumbbell is formed by two long helices (helix-7 and 12), which show high level of
conservation both structurally and evolutionary. PcrG specifically protects a region of PcrV extending from helix-12 to
helix-7, and encompassing the C-terminal globular domain. This fragment ΔPcrV(128–294) interacts with PcrG with high
affinity, comparable to the wild type interaction. Deletion of N-terminal globular domain leads to the oligomerization
of PcrV, but PcrG restores the monomeric state of PcrV by forming a heterodimeric complex. The N-terminal globular
domain (ΔPcrV(1–127)) does not interact with PcrG but maintains its monomeric state. Interaction affinities of various
domains of PcrV with PcrG illustrates that helix-12 is the key mediator of PcrG-PcrV interaction, supported by helix-7.
Bioinformatic analysis and study with our deletion mutant ΔPcrG(13–72) revealed that the first predicted intramolecular
coiled-coil domain of PcrG contains the PcrV interaction site. However, 12 N-terminal amino acids of PcrG play an
indirect role in PcrG-PcrV interaction, as their deletion causes 40-fold reduction in binding affinity and changes the
kinetic parameters of interaction. ΔPcrG(13–72) fits within the groove formed between the two globular domains of
PcrV, through hydrophobic interaction.
Conclusion: PcrG interacts with PcrV through its intramolecular coiled-coil region and masks the domains responsible
for oligomerization of PcrV at the needle tip. Also, PcrG could restore the monomeric state of oligomeric PcrV. Therefore,
PcrG prevents the premature oligomerization of PcrV and maintains its functional state within the bacterial cytoplasm,
which is a pre-requisite for formation of the functional translocon.
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The Gram negative bacterium Pseudomonas aeruginosa is
an opportunistic pathogen which causes acute infections
in immune-compromised individuals. It is the causative
agent of nosocomial pneumonia and other infections asso-
ciated with burns, wounds, urinary tract, and cystic fibro-
sis [1-3]. P. aeruginosa possesses a TTSS, which uses an
injectisome for delivery of bacterial toxic effector proteins
within the host cell. The injectisome comprises of a basal
structure and a needle complex. At the tip of the needle a
translocon is formed by a set of three translocator proteins.
This structure is essential for transport of the effector pro-
teins and regulation of TTSS [3-7]. Two of the transloca-
tors are hydrophobic (like PopB, PopD from Pseudomonas
sp. or YopB, YopD from Yersinia sp.) and form pores in
the host cell membrane [6-10]. While the hydrophilic
translocators (like PcrV from Pseudomonas sp. or LcrV
from Yersinia sp.), also known as V-antigen, form a
platform for the assembly of the hydrophobic translocators
[6,7,11]. The hydrophilic translocators act as protective
antigens against infection and are targets for the develop-
ment of vaccine [12].
PcrV is a regulator of TTSS. It is chaperoned by PcrG,
which itself is a cytoplasmic regulator of TTSS. Although,
PcrV is a secretory protein, PcrG is completely cytoplasmic
and both of these proteins regulate the TTSS independently
[13,14]. PcrV oligomerizes at the needle tip for formation of
the functional translocon. The C-terminal helix of PcrV is
essential for its oligomerization. For the regulation of TTSS,
PcrV exists in various conformational states. It alters
the structure of translocation apparatus hence, controlling
secretion of the effectors [15,16]. PcrV belongs to the
Ysc family of translocators, which includes LcrV, AcrV
(Aeromonas sp.). Other important family of translocators is
Inv-Mxi, which consists of IpaD, SipD and BipD proteins.
Translocators belonging to Inv-Mxi family possess two
distinct domains. The N-terminal domain shows simi-
larity with the common chaperones, suggesting a self-
chaperoning function of these translocators. This is contrary
to the behaviour of the translocators PcrV and LcrV, which
utilize their cognate chaperones PcrG and LcrG in the bac-
terial cytoplasm [17-20]. The crystal structure of LcrV de-
picts dumbbell shape with two globular domains. The grip
of the dumbbell is formed by two long helices [21]. PcrG
and PcrV form a 1:1 high affinity complex and the deletion
of the 24 C-terminal amino acids of PcrG does not alter
the affinity of the complex formation [14]. Comparatively,
little is known regarding the mechanism of regulation of
TTSS by PcrG, apart from the fact that it is a negative
regulator of TTSS, and C-terminal residues of PcrG regu-
late the effector secretion. Formation of PcrG-PcrV com-
plex is not essential for the regulation of TTSS, but it
confers stability to both the proteins within the bacterial
cytoplasm and prevents the misfolding of PcrV [13-15].The existing literature mainly focuses on the function
of PcrV with respect to the regulation of TTSS. In this
study, we have emphasized on the structural aspects of
PcrG-PcrV interaction and conclusively proposed a model
for the formation of PcrG-PcrV complex.
Results and discussion
PcrV retains the elongated conformation in the complex
with PcrG, but with structural alteration
Based on Far UV CD spectrum and thermal denaturation
curve, it was proposed that PcrV imparts structural stability
to PcrG. Also, it was established that PcrG-PcrV interaction
imparts stability to both the proteins [14]. The near UV CD
spectrum showed the absence of tertiary structure signal
for PcrG (Figure 1A). PcrV showed a negative signal at
285 nm (Figure 1A), which was almost in compliance with
the previously reported minimum at 284 nm [15]. However,
there was a shift of the minimum to 287 nm in case of
PcrG-PcrV complex and the negative signal was more
prominent in case of the complex structure (Figure 1A).
This indicated towards a structural alteration of PcrV in
presence of PcrG, in the complex. When PcrG was incu-
bated with 8-anilinonapthalene-1-sulfonate (ANS), it showed
almost similar spectrum to that of ANS (Figure 1B). This
observation can be attributed to the lack of solvent exposed
hydrophobic domains within PcrG, required for ANS bind-
ing. However, in the ANS-binding experiment, both PcrV
and PcrG-PcrV complex showed significant blue shift in the
λmax to 484 nm and 476 nm, respectively. Moreover, the
summation of PcrG-ANS and PcrV-ANS spectra was
significantly different from PcrG-PcrV-ANS spectrum,
revealing the differential structural moulding of both PcrG
and PcrV within the complex (Figure 1B).
Dynamic light scattering (DLS) profile of PcrV and PcrG-
PcrV revealed single predominant peaks corresponding
to hydrodynamic diameters of 6.503 nm and 7.531 nm,
respectively (Figure 1C). The estimated molecular weights
of 53.1 kDa for PcrV and 74.9 kDa for PcrG-PcrV, clearly
revealed their extended conformation. PcrV exists in a
monomeric physiological state with a molecular weight
of ~33 kDa. While PcrG-PcrV forms a 1:1 complex
with a molecular weight of ~46 KDa [14]. Similar to
PcrV, the elongated conformation was also observed
in the crystal structure of its close homologue LcrV
[21]. DLS experiments revealed that the hydrodynamic
diameter of LcrV and LcrG-LcrV were 7.75 nm and
8.71 nm, respectively, in the solution state. This indi-
cated towards the elongated conformation of LcrV in
individual form and complex form (Figure 1C). PcrG
and PcrV interaction is not essential for regulation of
TTSS by these proteins. However, the formation of
PcrG-PcrV complex provides structural stability to both
the proteins and aids in proper folding and export of
PcrV [13-15].
Figure 1 Near UV CD, ANS-fluorescence spectra, and DLS profile show structural stabilization and elongated conformation of the proteins.
A. Near UV CD signal recorded from 300 nm to 250 nm, shows negative signal for PcrV and PcrG-PcrV at 285 nm and 287 nm, respectively. PcrG shows
absence of tertiary structure signal. B. ANS-binding profile of proteins was scanned from 400 nm to 600 nm. Both PcrV and PcrG-PcrV exhibit a
blue-shift in the ANS-binding spectra, showing the presence of solvent exposed hydrophobic patches in the proteins. However, the spectrum
of PcrG was similar to that of ANS. C. DLS profiles of PcrV, PcrG-PcrV and LcrV, LcrG-LcrV with corresponding hydrodynamic diameters, confirm
an elongated conformation of the proteins.
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dumbbell shaped conformation
The homology model of PcrV was built by I-Tasser using
LcrV [PDB ID: 1R6F] as template, which has 37% sequence
identity with PcrV. The homology model was validated by
PROCHECK (Additional file 1, Additional file 2) [22-24].
This model has a C-score of −0.07, TM Score of 0.70 ± 0.12
and RMSD of 6.3 ± 3.8 Å. The cartoon representation of
the dumbbell shaped model of PcrV depicted the predom-
inance of α-helical structures, interspersed by coiled re-
gions, and few β-sheets. Out of the 12 α-helices in the
structure, helix-7 (128–158) and helix-12 (251–293)
are the longest. These two helices run anti-parallel to each
other and form the grip of the dumbbell. Two β-sheets
are localized between the 2nd and 3rd, and 4th and 5th
helices, respectively. There is a short helix and a long coil
region extending from residues 198–233 in the C-terminal,
which falls within the protective epitope region of PcrV
[19]. It is also evident from the orientation of PcrV on the
needle tip, that aforesaid region must be exposed to the
outer environment [7,19,25]. The N-terminal globular
domain is formed by α-1, α-2, β-1, α-3, α-4, β-2, α-5, α-6.
This domain is predicted to interact with the needle form-
ing protein of P. aeruginosa [7,25]. The C-terminal globulardomain forming the outer part of the needle tip comprises
of a short helix followed by α-8, α-9, a long coiled region
and α-10, α-11. The N and C-terminal globular domains
are structurally flexible due to their probable fate towards
insertions (Figure 2A) [16,19,20,25]. The helix-12 is pre-
ceded by a loop in the model which might provide flexibil-
ity to the helix for attaining different conformations [15,21].
The elongated conformation proposed by the DLS data also
corroborates with the dimensions of the dumbbell shaped
model, which is 8.1 nm in length and 4.68 nm in width.
The homology model was used to generate ConSurf
prediction model. This model is based on phylogenetic
relations and evolutionary changes between homologous
sequences [26]. The ConSurf model specified structurally
and functionally conserved residues in a graded fashion.
The helix-7, helix-12, the short helix, and the coil re-
gion preceding helix-12 showed maximum conservation.
Broadly, the grip of the dumbbell is highly conserved both
structurally and functionally (Figure 2B). From the multiple
sequence alignment (MSA) file, a high sequence identity
could be noticed between PcrV and its orthologs like
AcrV, LssV and LcrV, specifically within helix-7 (residues
137–157) and helix-12 (residue 250–287) (Additional file 3)
[27]. Sequence Logos of these two helices were generated
Figure 2 Homology model of PcrV and its analysis indicated the structurally and functionally conserved regions. A. Cartoon representation
of homology model of PcrV depicts a dumbbell shaped structure with N and C-terminal globular domains. Helices 7 and 12 form the grip of the
dumbbell. B. ConSurf predicted the structurally and functionally conserved residues within the homology model of PcrV, in a graded manner as shown
by the colour code. C. WebLogo generated sequence Logos of helix-7 and 12 of V-antigens. Sequences of helix-7 and 12 of PcrV were aligned with
the sequence Logos to determine the conserved positions.
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sequences of helix-7 and helix-12 of PcrV exhibited high
level of conservation when compared to the consensus se-
quences of the Logos. In case of helix-7 (31 residues long)
and helix-12 (43 residues long), 17 and 24 residues were
conserved, respectively (Figure 2C) [28].
Proteolytic digestion identified a specific region of PcrV
protected by PcrG
Proteolytic digestion of PcrV was carried out at different
time points with 1:500 dilution of α-chymotrypsin. The
digestion profile showed two predominant bands (frag-
ments) existing till 50 minutes. One band was close to
the 17 kDa marker and MS/MS sequence analysis showed
that this fragment approximately extended from helix-7 up
to helix-12 in the C-terminal of PcrV (Figure 3A, Additional
file 4). Another band was present between 10 kDa and
17 kDa. MS/MS sequence analysis revealed that this
fragment consists of bulk portion of the N-terminal,
and completely includes the helix-7 of PcrV (Figure 3A,
Additional file 5). Similar proteolytic digestion of PcrG-
PcrV (as done for PcrV) revealed the presence of an
extra band in between 17 and 26 kDa, corresponding
to 19487.0064 Dalton in addition to the two aforesaid
bands, as observed from the mass spectrometry profile
(Figure 3B & 3C, Additional file 6). So, it can be concluded
that PcrG specifically protects certain interacting region
of PcrV. MS/MS sequence analysis revealed that thisprotected region encompasses the entire C-terminal of
PcrV comprising of helix-12, C-terminal globular domain
and extending up to major portions of helix-7 (Additional
file 7).
PcrG restores the monomeric state of oligomeric
ΔPcrV(128–294) by forming a high affinity heterodimeric
PcrG-ΔPcrV(128–294) complex
Based on the results of proteolytic digestion, showing a
specific region of PcrV protected by PcrG, and bioinformatic
analysis showing the conservation at helix-12 and 7,
we designed a deletion mutant of PcrV comprising of
helix-7, the C-terminal globular domain and helix-12
(ΔPcrV(128–294)) (Figure 2B & 2C, Figure 3B & 3C,
Additional file 6, Additional file 7). The complementary
fragment of PcrV was also designed containing only
the N-terminal globular domain (ΔPcrV(1–127)). When
both ΔPcrV(1–127) and ΔPcrV(128–294) were incubated
with PcrG and purified by affinity chromatography, the
interaction studies showed that only ΔPcrV(128–294)
interacted with PcrG (Figure 4A). In Figure 4B, the region
corresponding to ΔPcrV(128–294) is highlighted in deep blue
colour in the homology model of PcrV. In order to check
the affinity and kinetics of interaction of ΔPcrV(128–294) and
PcrG, we used surface plasmon resonance (SPR). KD value
of 2.43 × 10-8 M confirmed the formation of a high affinity
complex between ΔPcrV(128–294) and PcrG. Although there
was a slight reduction in the affinity of the complex
Figure 3 Proteolytic digestion identified a specifically protected region of PcrV in presence of PcrG. A. and B. Proteolytic digestion
profiles of PcrV and PcrG-PcrV, respectively, with α-chymotrypsin from 10 to 50 minutes. Black arrows indicate the stable fragments generated
after proteolysis. C. The digestion patterns of PcrV and PcrG-PcrV shows the presence of a specifically protected region of PcrV in the PcrG-PcrV
complex, which is highlighted by a black arrow and a red star. L1 and L2 denote native PcrV and PcrG-PcrV. L3 and L4 denote PcrV and PcrG-PcrV,
respectively, cleaved by α-chymotrypsin after 30 minutes. M is the protein molecular weight marker (10, 17, 26, 34, 43, 55 kDa bands from bottom
to top).
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in the association and dissociation rates of the reaction
was observed (Figure 4C, Table 1) [14]. Size exclusion
chromatography (SEC) profile showed that ΔPcrV(128–294)
exists as an oligomeric species eluting at 60 ml, which
corresponds to a molecular weight ~193 kDa. We could
not assign a proper state to the oligomer due to the
elongated conformation of PcrV. The previous report
also emphasized on the propensity of PcrV towards
oligomerization on deletion of the N-terminal globular
domain [20]. Gebus et al. [15], observed dimeric to hex-
americ states of PcrV on oligomerization, and concluded
from further studies that V-antigens of Y. pestis and P.
aeruginosa could oligomerize into higher order ring like
structures with molecular weights greater than 130 kDa.
However, in the complex form, PcrG-ΔPcrV(128–294) showed
a shift in the elution volume to 77 ml corresponding to
a molecular weight of 41 kDa (actual mass of 1:1 PcrG-
ΔPcrV(128–294) complex is ~32 kDa), implying on the
restoration of the monomeric state of ΔPcrV(128–294) in
the complex. PcrG elutes at 83 ml corresponding to a mo-
lecular weight of ~31 kDa, indicating towards a dimericstate (actual mass of PcrG dimer is ~25 kDa) (Figure 4D).
Further, DLS was performed to corroborate the observation
of SEC and to check the existence of any aggregation state
of ΔPcrV(128–294). DLS studies showed that ΔPcrV(128–294)
forms oligomeric species with a hydrodynamic diameter
of 11.8 nm, suggesting a molecular weight greater than
200 kDa (Figure 4E). However, when equimolar concentra-
tion of PcrG is incubated with ΔPcrV(128–294), the higher
order oligomeric species attains a lower hydrodynamic
diameter of 7.3 nm, which corresponds to an elongated 1:1
heterodimeric complex of PcrG-ΔPcrV(128–294) (Figure 4E).
This reversion of oligomeric state of ΔPcrV(128–294) could
be visualized by native PAGE (Additional file 8). The 1:1
heterodimeric complex could also be seen by chemically
crosslinking PcrG and ΔPcrV(128–294) by ethylene glycol bis
[succinimidyl succinate] (EGS)-sulfonate (Figure 4 F). The
results depicted that the N-terminal globular domain
regulates the physiological state of PcrV. The N-terminal
globular domain does not interact with PcrG, but SEC
profile showed that it maintains a monomeric state and it
elutes at 88 ml corresponding to a ~21 kDa species (actual
mass of ΔPcrV(1–127) is ~15 kDa) (Figure 4G).
Figure 4 PcrG restores the monomeric state of oligomeric ΔPcrV(128–294) by forming a high affinity heterodimeric PcrG-ΔPcrV(128–294)
complex. A. SDS PAGE showing the interaction of PcrG with ΔPcrV(128–294) and ΔPcrV(1–127). When ΔPcrV(128–294) was incubated with PcrG and subjected
to Ni-NTA affinity chromatography, both ΔPcrV(128–294) and PcrG were seen in the elution fraction. However, when ΔPcrV(1–127) was incubated with PcrG,
only PcrG was seen in the elution. This revealed that only ΔPcrV(128–294) forms a complex with PcrG. B. The region corresponding to ΔPcrV(128–294) was
shown in deep blue colour in the homology model of PcrV. This region encompasses helix-7, C-terminal globular domain, and helix-12. C. Surface
plasmon resonance sensogram of ΔPcrV(128–294) and PcrG. D. Size exclusion chromatography profile of ΔPcrV(128–294), PcrG-ΔPcrV(128–294), and PcrG with
the corresponding SDS PAGE showing the proteins present in each of the peaks. E. The DLS profile of ΔPcrV(128–294), PcrG-ΔPcrV(128–294) complex, and PcrG
with corresponding hydrodynamic diameter. F. ΔPcrV(128–294) forms a 1:1 heterodimeric complex with PcrG, shown by chemical crosslinking with 0.5 mM,
1 mM and 2 mM EGS-sulfonate. G. Size exclusion chromatography profile of ΔPcrV(1–127) with corresponding SDS PAGE. M denotes the protein molecular
weight marker in SDS PAGE (10, 17, 26, 34, 43, 55 kDa bands from bottom to top).
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PcrG indicates that the location of PcrG-binding site could
be within the two long helices of PcrV. Oligomerization of
PcrV subunits at the tip of the needle is proposed to occur
by intramolecular exchange of helix-7 and helix-12 by
“domain swapping” mechanism and the last 41 amino
acids forming helix-12 is essential for oligomerization. De-
letion of the C-terminal helix inhibits the multimerizationTable 1 Kinetic parameters of interaction between deletion m
Kinetic parameter PcrG-PcrV ΔPcrG(1–74)-PcrV PcrG-Δ
KA (1/M) 6.4 × 10
7 6.4 × 107 4.11 ×
KD (M) 1.56 × 10
-8 1.56 × 10-8 2.43 ×
Ka (1/MS) 4.45 × 10
5 3.16 × 105 5.11 ×
Kd (1/S) 6.94 × 10
-3 4.91 × 10-3 1.24 ×
Table 1 Binding affinities, and association and dissociation rates of interaction betw
parameters of PcrG-PcrV interaction and ΔPcrG(1–74)-PcrV interaction were adaptedof PcrV and has post-secretory implications, abolishing
the bacterial cytotoxicity [15]. So, protection or masking
of these helices by PcrG, prevented the oligomerization
and misfolding of PcrV within the bacterial cytoplasm.
It also helped to maintain the functional form of PcrV by
formation of the heterodimeric complex of PcrG-PcrV in
the cytoplasm. The result established the neutral role of
the N-terminal domain of PcrV in interaction with PcrG.utants of PcrG and PcrV, were determined by SPR
PcrV(128–294) ΔPcrG(13–72)-PcrV ΔPcrG(13–72)-ΔPcrV(128–294)
107 1.75 × 106 1.61 × 106
10-8 5.7 × 10-7 6.21 × 10-7
102 1.71 × 104 2.72 × 101
10-5 9.78 × 10-3 1.69 × 10-5
een deletion mutants of PcrG and PcrV, were determined by SPR. Kinetic
from Nanao et al. [14].
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ance of the non-oligomeric state of PcrV and regulates the
secretion of PcrV through the injectisome. Specifically, de-
letion of 3–20 amino acids leads to defects in the secretion
of the PcrV [13]. Furthermore, the N-terminal globular
domain of PcrV interacts with the needle forming protein
PscF. Also, this domain of LcrV is essential for recruitment
of YopB in target cell membrane. These observations
prompted us to propose a chaperoning activity associated
with this domain, as seen in Inv-Mxi family of hydrophilic
translocators like IpaD, SipD, and BipD [3,7,19,25].
Helix-12 is the key mediator for PcrG-PcrV interaction and
helix-7 might support the interaction
From the proteolytic cleavage data, it was established
that PcrG protects the C-terminal helix-12 of PcrV and
major part of helix-7 (Figure 3B & 3C, Additional file 6,
Additional file 7). Lee et al. [13], reported that mutations
in C-terminal helix of PcrV affect PcrG-PcrV interaction.
The F279R mutation in helix-12 has a deleterious effect
towards PcrG interaction and L262D mutation abolished
PcrG binding. However, the entire region of PcrV involved
in PcrG-interaction is still unknown. To specifically assign
the PcrG-interaction domain of PcrV, we have dissected
PcrV into various fragments, comprising of a combination
of four domains (i.e. N-terminal globular domain, helix-7,
C-terminal globular domain, and helix-12).
Apart from the stable fragment of PcrV protected by
PcrG, which is ΔPcrV(128–294), we designed four more de-
letion fragments of PcrV to understand the role of various
domains of PcrV in PcrG-PcrV interaction. ΔPcrV(1–158)
comprises of the N-terminal globular domain and helix-
7; ΔPcrV(1–250) contains the N-terminal globular domain,
helix-7 and the C-terminal globular domain; ΔPcrV(128–250)
comprises of helix-7 and the C-terminal globular domain,
and ΔPcrV(159–294) contains the C-terminal globular
domain and helix-12. Molecular masses of all these deletion
mutants were checked by native mass spectrometry, and
their experimental masses were extremely close to their
theoretical masses. Quantitative binding of PcrG with
each of the deletion mutants of PcrV, was analyzed by
SPR. We have found that PcrG-ΔPcrV(159–294) has KD of
3.66 × 10-8 M. So, we observed a 1.5 fold reduction in
the binding affinity on deletion of helix-7, compared to
KD of PcrG-ΔPcrV(128–294) complex, however, the order of
interaction remains 10-8 M (Figure 5). Interactions of PcrG
with fragments of PcrV devoid of helix-12- ΔPcrV(1–158),
ΔPcrV(1–250), ΔPcrV(128–250) showed KD values 2.03 ×
10-7 M, 1.79 × 10-7 M and 2.47 × 10-7 M, respectively
(Figure 5). These results emphasized that deletion of
helix-12 leads to greater than 10 fold reduction in binding
affinity, when the binding affinities of ΔPcrV(128–294)
and ΔPcrV(128–250) were compared (Figure 5). By compar-
ing the binding affinity of ΔPcrV(1–158) and ΔPcrV(1–250),we conclude an insignificant role of the C-terminal globu-
lar domain in PcrG-PcrV interaction (Figure 5).
The above experimental evidences suggest that the main
PcrG-interaction domain is localized within helix-12. How-
ever, helix-7 also enables PcrG-PcrV complex formation, so
it might stabilize the PcrG-PcrV interaction due to the close
packing of the helices, as observed in the model. Lawton
et al. [29], identified certain residues within helix-7 of LcrV,
involved in LcrG-LcrV interaction. These residues occupy
crucial positions of the heptad repeats in helix-7; hence,
they are critical for the formation of intramolecular coiled-
coil and α7-α12 interaction. Mutagenesis of these residues
affects the binding between LcrV and LcrG [21,29,30].
Insertional and point mutagenesis identified residues in
helix-12 crucial for LcrG-LcrV interaction [30]. Therefore,
in LcrV, helix-7 as well as helix-12 possesses residues in-
volved in LcrG-LcrV interaction. Interestingly, mutation of
the residues in α7 of LcrV (involved in LcrG interaction)
affects multimerization of LcrV, which might be due to
disruption of intramolecular coiled-coil and α7-α12 inter-
action, but it allows the formation of the complex between
LcrG-LcrV [29]. Mutations in C-terminal helix-12 of PcrV
perturb the formation of the intramolecular coiled-coil
and abolish the oligomerization of PcrV, revealing that
formation of the coiled-coil is essential for oligomerization
of the V-antigen [15]. Also, PcrG could prevent the
oligomerization of PcrV, giving an indication that PcrG
binding might affect the intramolecular coiled-coil struc-
ture of PcrV. Based on the crystal structure of LcrV and
mechanism of LcrG-LcrV interaction mediated through
the heptad repeats of α7 of LcrV, Gebus et al. [15], pro-
posed that V-antigen could exist in a closed and an open
state. The closed state corresponds to the monomeric
shape of the V-antigen, while the open state renders α7
and α12 free for interaction with its partners [15,21,29].
Therefore, the formation of intramolecular coiled-coil is
not absolutely essential for the interaction of V-antigen
with its partners. These facts corroborate our SPR ana-
lysis, where we have observed that the presence of either
of the two helices (7 or 12) in PcrV enables the complex
formation with PcrG, because both the helices contain
residues for PcrG interaction. Structural stabilization by
intramolecular coiled-coil structure is not an absolute
necessity for PcrG-PcrV interaction. However, the affinity
of the interaction is reduced due to the changes in the
local structure in absence of one of the helices. Single mu-
tation of L262D in helix-12 of PcrV, abolishes PcrG-PcrV
interaction [13]. The corresponding residue L291 in LcrV
is not only involved in LcrG interaction, but also present
within the zipper motif and takes part in α7-α12 inter-
action [30]. Importantly, L262D mutation inhibits the
oligomerization of PcrV and had a profound effect on
bacterial cytotoxicity [13,15]. Therefore, under the influence
of this mutation V-antigen attains a monomeric shape
Figure 5 Interaction of various domains of PcrV with PcrG. KD values estimated by SPR, reveal the binding affinities of various deletion
mutants of PcrV with PcrG. Higher affinity of interaction was observed when helix-12 is present in the deletion mutant, but presence of helix-7
also allows the interaction.
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not favourable for the interaction of V-antigen with its
binding partners [15]. Changing the hydrophobic leu-
cine to charged aspartic acid residue might enforce a
local structural change within both the helices due to
their close packing. So, it would be interesting to test
whether other single amino acid substitution in the
helix-12 leading to oligomerization defects, could also
abolish PcrG-PcrV interaction.
Intramolecular coiled-coil region of PcrG contains the
PcrV interaction site with an indirect role of N-terminal
residues of PcrG in the interaction
24 C-terminal amino acids of PcrG, exhibit disorder and
absence of secondary structure [14]. Further analysis of
PcrG with various disorder prediction servers revealed
that a few amino acids in the N-terminal and a patch in
the C-terminal are disordered. PrDOS predicted disorder
region of 1–13 amino acids in the N-terminal and 73–98
in the C-terminal (Figure 6A) [31]. DisEMBL 1.5 and
Disopred version-2.0 provided almost similar predictions
(Additional file 9) [32,33]. Controlled proteolytic digestion
with elastase produced a fragment of PcrG with molecular
weight of 9782.1182 Dalton, with an intact C-terminal,
as revealed by mass spectrometry and MS/MS sequence
analysis (Figure 6B, Additional file 10, Additional file 11).The C-terminal region is an essential part of PcrG since,
deletion of this region leads to deregulation of effector
secretion [13]. Also, MSA showed that there is substantial
homology and conservation in the C-terminal of PcrG
(Additional file 12) [27]. Though the C-terminal of PcrG
is disordered, it is inaccessible to ANS and protected from
proteolytic digestion. This may be due to the formation of
compact structure.
When PcrG was divided into two fragments one com-
prising of amino acid 2–40 and the other consisting of
amino acid 41–95, only the former fragment interacted
with PcrV [13]. Also, PcrG and its homologs like AcrG,
LssG and LcrG show maximum identity and conservation
between residues 20–35 (Additional file 12) [27]. The
COILS/PCOILS server predicted that amino acids 9–31
constitute the first intramolecular coiled-coil region in PcrG
(Additional file 13) [34]. The N-terminal intramolecular
coiled-coil region is essential in case of LcrG for its inter-
action with LcrV [29,35]. Based on the above results, we
have designed a deletion mutant of PcrG, comprising of
amino acids 13–72. This deletion mutant (ΔPcrG(13–72))
interacts with PcrV, undermining the role of first 12
N-terminal residues of PcrG in PcrG-PcrV interaction.
Similar to PcrG, ΔPcrG(13–72) also exists in a dimeric state, as
detected by native mass spectrometry. The theoretical
mass of ΔPcrG(13–72) dimer is 17649.6 Da and the observed
Figure 6 ΔPcrG(13–72) containing first intramolecular coiled-coil region of PcrG shows interaction with PcrV and ΔPcrV(128–294). A.
Disordered regions in PcrG predicted by PrDOS. The image was directly taken from the server. B. Proteolytic digestion of PcrG with elastase from
30 to 150 minutes. Ctrl denotes native PcrG and M is the protein molecular weight marker (10, 17, 26, 34 kDa bands from bottom to top).
C. Native mass spectrometry shows the dimeric state of ΔPcrG(13–72). D. Surface plasmon resonance sensogram of ΔPcrG(13–72) and PcrV shows a
40 fold reduction in affinity of interaction on deletion of the 12 N-terminal amino acids of PcrG. E. Surface plasmon resonance sensogram of
ΔPcrG(13–72) and ΔPcrV(128–294).
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(Figure 6C). However, due to the deletion of the predicted
disordered region, the helicity of ΔPcrG(13–72) increases
to ~24% (data to be published).
Deletion of 24 C-terminal residues of PcrG does not have
any effect on the affinity of PcrG-PcrV interaction [14].
After deletion of the first 12 N-terminal amino acids
and the 26 C-terminal amino acids of PcrG, ΔPcrG(13–72)
could still form a high affinity complex with PcrV (KD
5.7 × 10-7 M). But there are certain alterations in the asso-
ciation and dissociation kinetics (Figure 6D, Table 1) [14].
Since, amino acid 2–40 of PcrG interacts with PcrV [13]
and our deletion mutant of PcrG containing residue 13–72,
also interacts with PcrV, we predict that residues 13–40
of PcrG form the core region for PcrG-PcrV interaction.
Moreover, this region contains almost the entire intramo-
lecular coiled-coil and amino acids A19, S26 and L33.
These three amino acids are conserved and are key residues
involved in LcrG-LcrV interaction [34,35]. Although the
deletion of 12 N-terminal residues abolishes LcrG-LcrV
interaction [35], similar deletion of 12 N-terminal residues
in PcrG could still allow it to form a high affinity complex
with PcrV. However, a 40-fold reduction in bindingaffinity was noticed when the KD value of PcrG-PcrV
and ΔPcrG(13–72)-PcrV were compared (Figure 6D, Table 1)
[14]. ΔPcrG(13–72) also interacts with ΔPcrV(128–294) with a
slight reduction in the affinity (KD 6.21 × 10
-7 M),
compared to full length PcrV (Figure 6E, Table 1). It may
predict an indirect involvement of the N-terminal in the
interaction between PcrG and PcrV. The structural do-
mains of PcrG involved in PcrG-PcrV interaction, might
differ from those of LcrG in LcrG-LcrV interaction.
During the interaction of ΔPcrG(13–72) with ΔPcrV(1–158),
ΔPcrV(1–250), and ΔPcrV(128–250), the KD reduces to micro-
molar range. This high reduction in the binding affinity
could be attributed to the absence of helix-12 of PcrV and
12 N-terminal residues of PcrG. But ΔPcrG(13–72) and
ΔPcrV(159–294) (fragment containing helix-12) still show
nanomolar range of interaction, emphasizing the significant
role of helix-12 in the PcrG-PcrV interaction (Figure 7). In
spite of deletion of various domains of PcrV and PcrG,
presence of either of the helices (7 or 12) in PcrV and intra-
molecular coiled region of PcrG enables the formation of
the complex. These observations further established that
helix-7 or 12 of PcrV and intramolecular coiled-coil of PcrG
contain the sites for PcrG-PcrV interaction.
Figure 7 Interaction of various domains of PcrV with ΔPcrG(13–72). KD values estimated by SPR, show the binding affinities of various deletion
fragments of PcrV with ΔPcrG(13–72).
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ΔPcrG(13–72) in a groove formed between two globular
domains of PcrV
A model of the deletion mutant of PcrG (ΔPcrG(13–72))
was generated using I-Tasser (Additional file 14). Since,
experimental 3D structures of orthologs of PcrG were
unavailable; I-tasser used a threading algorithm. Deletion
of the disordered regions of PcrG led to a significant im-
provement in the quality of the model. C-score and the
TM Score of ΔPcrG(13–72) model are −1.5 and 0.52 ± 0.12,
respectively, which satisfied the I-Tasser cut off for a cor-
rect model, and confirmed a similar topology between the
model and the templates. The model was further validated
by PROCHECK (Additional file 15) [22-24]. However,
template proteins selected by threading programmes of
I-Tasser were not orthologous to the modelled protein,
and the process is based on prediction of similar fold
between the proteins. If not the actual state of PcrG, the
model provides the basic scaffold structure to estimate the
binding site of PcrV, which was already verified by experi-
mental techniques. The model of ΔPcrG(13–72) represents
four helices interspersed by coiled regions. The predicted
residues of PcrG involved in PcrV-binding, exactly map to
the first two helices of the model (shown in orange colour)
[Figure 4A]. Molecular docking studies were performed
using ZDOCK version ZD 3.0.2, where PcrV was designatedas the receptor and ΔPcrG(13–72) as the corresponding
ligand. The best model obtained from docking studies
was selected and validated by PROCHECK [24,36]
(Additional file 16, Additional file 17). The spacefill model
of ΔPcrG(13–72)-PcrV complex depicted that the binding
pocket of ΔPcrG(13–72) was located within the groove (or
grip), in between the two globular terminal domains of
PcrV (Figure 8B). The cartoon representation showed that
the first two helices of ΔPcrG(13–72), which overlap with
the first predicted intramolecular coiled-coil domain,
specifically interacts with helix-7 and helix-12 of PcrV
(Figure 8C). These observations further confirmed the
fact that 13–40 residues of PcrG and two long helices
of PcrV are the key mediators for the formation of the
complex. Figure 8D depicted the surface representation
of ΔPcrG(13–72)-PcrV complex, where the hydrophobic
residues were coloured in yellow. This model shows
that ΔPcrG(13–72) and PcrV interact through a hydropho-
bic interface corroborating the concept of hydrophobic
residues being involved in interaction of V-antigen with
its regulator [13,29,30,35].
Conclusions
PcrG and PcrV form a high affinity complex, which confers
stability and maintain the functional physiological states
of both the proteins within the bacterial cytoplasm [13,14].
Figure 8 Molecular docking fits ΔPcrG(13–72) into the groove formed between the two globular domains of PcrV. A. Schematic and
Cartoon representation of ΔPcrG(13–72) model, with the first two helices shown in orange colour. B. Spacefill model of PcrG-PcrV complex obtained
from molecular docking studies (ΔPcrG(13–72) was shown in blue and PcrV in grey colour), depicts that ΔPcrG(13–72) localizes within a groove formed
between the two globular domains of PcrV. C. Cartoon representation of model of ΔPcrG(13–72)-PcrV complex. The interacting regions of the ΔPcrG(13–72)
was shown in orange and that of PcrV was shown in blue, as represented in their respective models. D. Surface representation of ΔPcrG(13–72)-PcrV
complex, where ΔPcrG(13–72) and PcrV were shown in green and magenta, respectively. The hydrophobic amino acids were coloured in yellow. This
model reveals that the interface of interaction between ΔPcrG(13–72) and PcrV is mainly hydrophobic.
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formation, both in individual and in complex form. PcrG
protects a specific region of PcrV extending from helix-7
to helix-12, encompassing the C-terminal globular domain,
and devoid of the N-terminal globular domain. However,
the deletion of the N-terminal globular domain of PcrV
leads to its oligomerization, which could be reverted back
by PcrG. Therefore, PcrG can restore the monomeric form
of oligomer formed by PcrV. It was seen that helix-12
of PcrV plays the key role in PcrG-PcrV interaction,
supported by helix-7. N and C-terminal globular domains
have neutral roles in the interaction. However, the
N-terminal globular domain of V-antigen maintains a
monomeric state. It interacts with needle forming proteinPscF and recruits hydrophobic translocator in the target
cell membrane, thereby, indicating towards a chaperoning
function [7,19,25].
Interestingly, formation of the functional translocon
capable of targeting effectors within the host cell requires
oligomerization of PcrV at the needle tip [3-7,11,15,25].
Since, the PcrG interaction domain overlaps with the
oligomerization domain of PcrV, PcrG could potentially
stop the oligomerization of PcrV by docking into the
groove formed by helix-7 and helix-12. The intramolecular
coiled-coil region of PcrG contains the PcrV binding
domain, but unlike LcrG, the 12 N-terminal residues of
PcrG only have an indirect role in PcrG-PcrV interaction.
To conclude, PcrG prevents the premature oligomerization
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http://www.biomedcentral.com/1472-6807/14/5of PcrV and maintains its functional state within the bac-
terial cytoplasm, which is a pre-requisite for the formation
of functional translocon.
Methods
Design of expression vectors
The genes of pcrG, pcrV and pcrG-pcrV, ΔpcrG(13–72),
ΔpcrVs (deletion constructs of pcrV) were amplified by
PCR, using the chromosomal DNA of P. aeruginosa strain
2192. pcrG was cloned with EcoRI and HindIII, using sense
primer TAGAATTCTATGGGCGACATGAACGAA and
antisense primer AATAAGCTTTCAGATCAACAAGCC
ACG in pETDuet-1. ΔpcrG(13–72) was cloned in pET-28a
(+) with NdeI and XhoI, using sense primer TTAGGAT
CCATATGCGGGCGACCGTCCAGGCC and antisense
primer TTACTCGAGTTAGCGCCGCAGTTCGGCCAG.
pcrV, ΔpcrV(1–127), ΔpcrV(1–158), and ΔpcrV(1–250) were
cloned in pET-22b-Δ50CPD with NdeI and EcoRI, using
sense primer AATCCATGGAACATATGGAAGTCAGA
AACCT and antisense primers TAAGAATTCGGGATCG
CGCTGAGAATGTCGC, TAAGAATTCGGCTTGCCG
TCCTGGGTCTG, TAAGAATTCGGCTTGGCCGAC
AGCGCGGC, and TAAGAATTCGGCGGACGCGAGC
GGTCGCT, respectively. ΔpcrV(128–294) and ΔpcrV(128–250)
were cloned in pET-22b-Δ50CPD with NdeI and EcoRI,
using sense primer AATCCATGGAACATATGCGCAA
GGCGCTGCTCGAC and antisense primers TAAGAAT
TCGGGATCGCGCTGAGAATGTCGC and TAAGAA
TTCGGCGGACGCGAGCGGTCGCT, respectively. ΔpcrV
(159–294) was cloned in pET-28a (+) with NdeI and HindIII,
using sense primer AATCCATGGAACATATGCAGG
GCATCAGGATCGAC and antisense primer TTAAAGC
TTCTAGATCGCGCTGAGAAT. pcrG-pcrV was cloned
in pETDuet-1 with EcoRI and HindIII, using sense primer
of pcrG TAGAATTCTATGGGCGACATGAACGAA and
antisense primer of pcrV TTAAAGCTTCTAGATCGCG
CTGAGAAT. The restriction sites were marked in bold
letters. E. coli Top10 was used as the cloning strain.
Purification of proteins
The proteins were expressed in BL21 DE3 by culturing
in Luria Bertani medium and induction was carried with
1 mM IPTG for 4 hours at 37°C. Only ΔPcrG(13–72) was
induced overnight at 22°C. 1 mM phenylmethanesulfonyl
fluoride was used as protease inhibitor. PcrG, ΔPcrG(13–72)
and PcrG-PcrV have N-terminal 6X histidine tag. These
proteins were purified using standard nickel-nitrilotriacetic
acid (Ni-NTA) affinity chromatography. A step gradient
of immidazole was applied in 25 mM Tris–HCl (pH-8)
and 150 mM NaCl buffer, for removing the non-specific
proteins and eluting the desired protein. PcrV and its
deletion mutants (ΔPcrV(1–127), ΔPcrV(1–158), ΔPcrV(1–250),
ΔPcrV(128–250), and ΔPcrV(128–294)) were fused to a cysteine
protease domain (CPD) at their C-terminal. This CPDpossesses a C-terminal histidine tag. The fusion product
of the target protein and CPD is engineered in such a
manner that inositol hexokisphosphate recognizes a
specific leucine residue and cleaves exactly at the junction
of the PcrV and the CPD. PcrV-CPD was immobilized in
Ni-NTA affinity column and treated with 500 μM inositol
hexokisphosphate in 25 mM Tris–HCl (pH-7.5) and
150 mM NaCl buffer. Inositol hexokisphosphate cleaves at
the junction of PcrV and CPD to release PcrV (without
histidine tag) from the affinity column, and CPD with the
C-terminal histidine tag remains attached with the Ni-
NTA. The deletion mutants of PcrV were purified in a
similar way. So, we obtain PcrV and its various forms
without a histidine tag for further downstream experi-
ments. For detailed procedure refer Shen et al. [37].
ΔPcrV(159–294) had localized in the inclusion bodies.
The inclusion bodies were denatured using 6 M guanidium
hydrochloride. ΔPcrV(159–294) was refolded by slow dialysis
in 25 mM Tris–HCl (pH-8), 150 mM NaCl and 10% gly-
cerol buffer and subjected to Ni-NTA chromatography.
Further the histidine tag of ΔPcrV(159–294) was removed by
thrombin digestion which cleaves the leader sequence. All
the proteins were checked for their purity and molecular
weight by native mass spectrometry. For purification of
PcrG-ΔPcrV(128–294), PcrG was immobilized in the Ni-
NTA column and incubated with ΔPcrV(128–294) (without
histidine tag). The column was washed thoroughly to
remove any unbound protein and protein was eluted by
a step gradient of immidazole in 25 mM Tris–HCl (pH-8)
and 150 mM NaCl buffer. Both the proteins were observed
in the elution fraction. Similar incubation of PcrG with
ΔPcrV(1–127) and subsequent elution from the affinity
column showed the presence of ΔPcrV(1–127) in wash frac-
tion and PcrG in elution fraction, revealing that ΔPcrV(1–127)
is not forming a complex with PcrG. Purified proteins
were dialyzed to remove immidazole or 500 μM inositol
hexokisphosphate, in buffer according to the need of the
downstream experiments.
Size exclusion chromatography
Proteins purified by Ni-NTA chromatography were di-
alyzed in 25 mM Tris–HCl (pH-7.4) and 150 mM NaCl
(SEC buffer). HiLoad 16/60 Superdex 200 pg column
was equilibrated in the same SEC buffer. Proteins (2–5 mg/
ml) were injected into the column and a flow rate of
1 ml/min was maintained throughout the chromatog-
raphy. Fractions corresponding to the peaks in SEC
were collected and observed in SDS PAGE. For calibra-
tions of the SEC column, following gel filtration markers
were used (molecular weight and corresponding elution
volumes are indicated): Ferritin (440 kDa ~ 51 ml), Al-
dolase (158 kDa ~ 62 ml), Ovalbumin (43 kDa ~ 76 ml),
Carbonic anhydrase (29 kDa ~ 84 ml), Ribonuclease A
(13.7 kDa ~ 92 ml).
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Near UV CD spectra were recorded by Jasco J-815 spectro-
photometer. Spectra were recorded for 20 μM of proteins
from 300 to 250 nm with a scan speed of 10 nm/min. 1 cm
path length cuvette was used. Proteins were dialyzed and
diluted in 10 mM sodium phosphate (pH-7.4) and 50 mM
NaCl buffer. Buffer spectrum was subtracted from the
protein CD spectra.
ANS fluorescence spectroscopy
The fluorescence measurements were recorded using Jasco
FP-6500 fluorimeter. ANS emission spectra were moni-
tored from 400 to 600 nm with a scan speed of 50 nm/min,
using a 1 cm path length cuvette. Both the protein and the
ANS were prepared in 10 mM sodium phosphate (pH-7.4)
and 50 mM NaCl buffer. 2 μM of protein was used and up
to 30 μM ANS was incubated with the protein. The buffer
spectrum was subtracted from the ANS and protein fluor-
escence spectra.
Dynamic light scattering
DLS profile was obtained using a Malvern-Zetasizer nano
ZS DLS instrument. The Proteins were concentrated to
2–5 mg/ml and filtered using a 0.22 micron filter to re-
move any aggregate. Molecular weight corresponding to
the experimental hydrodynamic diameter was calculated
using the software for the instrument.
Homology modelling, ConSurf and WebLogo analysis,
and molecular docking of ΔPcrG(13–72) and PcrV
The spatial model of PcrV was generated by I-Tasser server
using the structure of LcrV from Yersinia pestis (PDBID:
1R6F) as the template. The sequence of PcrV was loaded in
the FASTA format to I-Tasser as the input file. Additional
restrained, or templates were not assigned by the user.
ΔPcrG(13–72) is also modelled by I-Tasser using a threading
approach, where the threading programmes of I-tasser
assigned the top 10 threading templates. The best threading
templates for ΔPcrG(13–72) have PDBID: 2ZB9, 2Q24,
3SHG, 1GJS, 2B8I, 1LLW, 1ZBP, 2B8I, and 2R78 [22,23].
From the output file the best model was represented in
PyMOL Molecular Graphics System [38]. The PDB file of
the best model of PcrV generated by I-tasser was submitted
as input to the ConSurf server. The default parameters of
the server were used for the prediction. To generate the
final model the output file- ConSurf modified PDB was
loaded in PyMOL, and conservation code information in
the script consurf_new.py was ran [26,38]. WebLogo
server was used to generate sequence Logos of helix-7
and helix-12 of V-antigens and the sequences of corre-
sponding helices of PcrV were aligned with these sequence
Logos. MSA of helix-7 and helix-12 of proteins belonging
to LcrV family was loaded as input [28]. To generate a
model of ΔPcrG(13–72)-PcrV interaction by moleculardocking, The PDB file of PcrV was loaded as the receptor
and ΔPcrG(13–72) was loaded as the ligand to the Z-Dock
server (version ZD 3.0.2) [36]. Finally, best model was se-
lected from top 5 predictions and represented using Jmol
and PyMOL [38,39]. All the models were further checked
and validated by PROCHECK [24].
Multiple sequence alignment, disorder and
coiled-coil prediction
Multiple sequence alignment profile of PcrG and PcrV with
their respective homologs, were generated using MultAlin
interface [27]. Disordered region in PcrG were predicted by
PrDOS, DisEMBL 1.5 and Disopred version 2.0 [31-33].
COILS/PCOILS server from expasy predicted the intra-
molecular coiled-coil region within PcrG [34].
Proteolytic digestion of PcrV, PcrG-PcrV with
α-chymotrypsin and PcrG with elastase
PcrV, PcrG-PcrV and PcrG were dialyzed in 10 mM hepes
(pH-7.4) and 150 mM NaCl. Proteases α-chymotrypsin
and elastase from Proti-Ace Kit of Hampton research was
diluted to 0.02 μg/μl by Proti-Ace dilution buffer from an
initial stock of 1 μg/μl of protease in deionised water. 1 μl
of protease from the diluted stock (0.02 μg/μl) was used
for 10 μg of protein. Proteolytic digestion was carried out
at 37°C for different time points and SDS PAGE sample
lysis buffer was used to stop the protease activity. Finally
the products obtained after digestion, were analyzed by
SDS PAGE.
Native mass spectrometry
Native proteins as well as the proteolytic digestion products
of PcrV, PcrG-PcrV, and PcrG were diluted to 0.5-1.0 mg/
ml concentration using HPLC water and immediately
spotted on the MALDI target plate. Proteolytic digestions
were stopped by trifluoroacetic acid present in the α-cyano
hydroxyl cinnamic acid (CHCA) matrix. Mass was analyzed
using an Applied Biosystem 4700 Proteomics Analyser 170.
MS/MS sequence analysis of different fragments of PcrG,
PcrV and PcrG-PcrV
After a specific time point, the digestion fragments of
PcrG, PcrV and PcrG-PcrV were separated by SDS PAGE.
The gel was stained with coomassie R-250 and washed
with distilled water. The bands were excised from SDS
PAGE and In-Gel tryptic digestion was carried out using
trypsin gold from Promega. The “In-Gel tryptic digestion
and MS/MS analysis” protocol provided by Promega was
followed. Only exceptions to protocol are: the proteins were
eluted in 40 mM ammonium bicarbonate, 10% acetonitrile
and 0.3% trifluoroacetic acid buffer. During MS/MS ana-
lysis CHCA was used as matrix and prominent peaks were
identified by MS after trypsinolysis. Peptides corresponding
to the prominent peaks were further fragmented by laser
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MSDB database of MASCOT search engine, using GPS
Explorer Software (version 3.6) [40].
Chemical crosslinking
Chemical crosslinking was performed using water soluble
crosslinker EGS-sulfonate. The proteins were dialyzed
in 10 mM hepes (pH-7.4) and 150 mM NaCl. The cross
linking reactions were carried out at room temperature
for 30 minutes with 0.5 mM, 1 mM, and 2 mM of EGS-
sulfonate, and finally stopped by addition of sample lysis
buffer of SDS PAGE. The crosslinked proteins were an-
alyzed in 12% SDS PAGE.
Surface plasmon resonance
Surface plasmon resonance binding analysis was performed
by using a BIACORE 3000 systems and NTA sensor chip
(GE Healthcare Life Sciences). Initially, both the flow
cells (experiment and the reference cell) were thoroughly
washed, and equilibrated with running buffer. Nickel
chloride solution was charged in the experiment cell for
the binding of nickel to the NTA sensor chip. According
to the instruction manual of GE Healthcare Life Sciences
for Biacore systems, the reference cell was maintained as
non activated flow cell and treated with similar concentra-
tion of analyte as used in the experiment cell. Histidine
tag PcrG and ΔPcrG(13–72) were used as ligands and
immobilized on the Ni-NTA surface in experiment cell.
PcrV and its deletion mutants were used as analytes. All
the proteins were dialyzed in the running buffer (10 mM
hepes (pH-7.4), 150 mM NaCl and 50 μM EDTA). Very
low concentration of EDTA was recommended in the run-
ning buffer to minimize non specific binding. In absence
of the ligand, analyte showed negligible interaction with
the activated flow cell. 20 μl of 50–100 μg/ml concentra-
tion of the ligand was charged for initial coupling to
Ni-NTA sensor chip and unbound ligand was thoroughly
washed by the running buffer. Binding kinetics were deter-
mined by passing PcrV and ΔPcrV (s) (deletion mutants)
at different concentration ranging from 10 nM to 400 nM
over PcrG and ΔPcrG(13–72). A flow rate of 5 μl/min
and temperature of 25°C was maintained throughout
the experiment. Binding constants and forward and back-
ward rates of reactions were determined by BIAevaluation
software version 4.1, using a Langmuir binding model.
In all the cases, the reference cell was subtracted from
the experiment cell by the software to eliminate any RU
change occurring due to non specific binding.
Availability of supporting data
The data sets supporting the results of this article are
included within the article (and its additional files). The
mass spectrometry profiles and MS/MS sequence analysis
of proteolytically digested protein fragments are given inAdditional files 4, 5, 6, 7, 10, and 11. The PDB files and
corresponding PROCHECK analysis of the models of
the proteins are given in Additional files 1, 2, 14, 15, 16
and 17.Additional files
Additional file 1: Homology model of PcrV. PDB file of the homology
model of PcrV was provided according to the editorial requirement.
Additional file 2: Ramachandran Plot for homology model of PcrV.
For Validation of homology model of PcrV, PROCHECK server was used,
which generated the corresponding Ramachandran Plot showing residues
in the most favoured, allowed and disallowed region in the model.
Additional file 3: Multiple sequence alignment of PcrV. Identity and
similarity in the sequence of PcrV and its homologs (hydrophilic
translocators of Ysc family) are shown.
Additional file 4: MS/MS sequence profile of 1st proteolytic
digestion fragment of PcrV. Sequence of the approximate region
corresponding to the 1st proteolytic digestion fragment of PcrV, as
revealed by MS/MS sequence analysis.
Additional file 5: MS/MS sequence profile of 2nd proteolytic
digestion fragment of PcrV. Almost entire sequence of the region
corresponding to the 2nd proteolytic digestion fragment of PcrV, as
revealed by MS/MS sequence analysis.
Additional file 6: Mass spectrometry profile of specifically
protected fragment of PcrV (in presence of PcrG) during proteolytic
digestion. Molecular weight of the protected fragment of PcrV in
presence of PcrG was estimated by mass spectrometry.
Additional file 7: MS/MS sequence profile of specifically protected
fragment of PcrV, in presence of PcrG during proteolytic digestion.
Almost entire sequence of the region corresponding to the specifically
protected fragment of PcrV in presence of PcrG during proteolytic
digestion, as revealed by MS/MS sequence analysis.
Additional file 8: Native PAGE showing oligomeric state of ΔPcrV
(128–294), and heterodimeric state of PcrG-ΔPcrV(128–294). Both ΔPcrV
(128–294) and PcrG-ΔPcrV(128–294) complex were run on the native PAGE.
Since, there is no denaturation of the proteins the greater migration of
PcrG-ΔPcrV(128–294) compared to ΔPcrV(128–294), shows reversion of the
oligomeric state to a lower order species, may be to a heterodimeric form.
Additional file 9: Disordered region of PcrG predicted by DisEMBL
1.5, Disopred version 2.0. DisEMBL 1.5, Disopred version 2.0 disorder
prediction servers predicting the disordered regions (regions lacking
proper secondary structure) within PcrG, by various algorithms used by
these servers.
Additional file 10: Mass spectrometry profile of the proteolytically
digested fragment of PcrG. Molecular weight of the proteolytically
digested fragment of PcrG was estimated by mass spectrometry.
Additional file 11: MS/MS sequence profile of proteolytically
digested fragment of PcrG. Sequence of the approximate region
corresponding to the digested fragment of PcrG, as revealed by MS/MS
sequence analysis.
Additional file 12: Multiple sequence alignment of PcrG. Identity
and similarity in the sequence of PcrG and its homologs, are shown.
Additional file 13: Coiled-coil regions of PcrG predicted by
COILS/PCOILS. Probablity of occurrence of intramolecular coiled-coil
regions (essential for protein-protein interaction) within PcrG, predicted by
COILS/PCOILS server, is shown.
Additional file 14: Model of ΔPcrG(13–72). PDB file of the model of
ΔPcrG(13–72) was provided according to the editorial requirement.
Additional file 15: Ramachandran Plot for the model of ΔPcrG(13–72).
For Validation of the model of ΔPcrG(13–72), PROCHECK server was used,
which generated the corresponding Ramachandran Plot showing residues
in the most favoured, allowed and disallowed region in the model.
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http://www.biomedcentral.com/1472-6807/14/5Additional file 16: Model of ΔPcrG(13–72)-PcrV. PDB file of the Model
of ΔPcrG(13–72)-PcrV was provided according to the editorial requirement.
Additional file 17: Ramachandran Plot for the model of
ΔPcrG(13–72)-PcrV generated by molecular docking. For Validation
of the model of ΔPcrG(13–72)-PcrV, PROCHECK server was used, which
generated the corresponding Ramachandran Plot showing residues in
the most favoured, allowed and disallowed region in the model.
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